The biotech company Moderna plans to start its 30,000-participant Phase 3 trial of its experimental Covid-19 vaccine on July 27, according to an entry posted on clinicaltrials.gov, a U.S. government registry of drug trials.
Moderna (ticker: MRNA) confirmed in an email to Barron’s that it had set an estimated start date for the trial of July 27. The start date would meet the company’s announced target of beginning its Phase 3 trial in July, although it is later than the July 9 start previously announced by some of the investigators involved. The company’s CEO has said that he aims to have efficacy data by Thanksgiving.
barrons.com/articles/modern...
&